In a report released today, Maury Raycroft from Jefferies reiterated a Hold rating on Affimed (NASDAQ: AFMD), with a price target of $1.80. The company’s shares opened today at $1.55.
According to TipRanks.com, Raycroft is a 5-star analyst with an average return of 27.2% and a 59.3% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Atara Biotherapeutics, and Intellia Therapeutics.
Affimed has an analyst consensus of Hold, with a price target consensus of $1.80.
See today’s analyst top recommended stocks >>
Based on Affimed’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $9.54 million. In comparison, last year the company had a GAAP net loss of $8.75 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Affimed NV is a clinical stage biopharmaceutical company, which engages in discovering and developing highly targeted cancer immunotherapies. The company has three proprietary platform technologies which includes: NK-cell TandAbs, T-cell TandAbs and Trispecific Abs. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
Read More on AFMD:
